Pain – Society of Cannabis Clinicians https://www.cannabisclinicians.org Educating Healthcare Professionals about the Medical Use of Cannabis Mon, 02 Oct 2023 21:41:37 +0000 en-US hourly 1 https://wordpress.org/?v=6.2.3 https://www.cannabisclinicians.org/wp-content/uploads/2020/07/cropped-scc-flavicon-32x32.png Pain – Society of Cannabis Clinicians https://www.cannabisclinicians.org 32 32 Cannabinoid modulations of pain and stress related circuits https://www.cannabisclinicians.org/2023/10/02/cannabinoid-modulations-of-pain-and-stress-related-circuits/ Mon, 02 Oct 2023 21:41:37 +0000 https://www.cannabisclinicians.org/?p=29344 In the past decade, significant advancements have been made in understanding the brain regions and neuronal circuits regulating neurological behaviors. The endocannabinoid (eCB) system, which is ubiquitously distributed in the brain and extensively involved in synaptic modulation, has been believed to play potential roles in neuronal circuit processes and related disorders. Although eCB-based pharmacological studies have made some clinical achievements, they still often encounter conflicting reports or undesired effects due to global manipulation of manifold brain regions and neuronal circuits, which impede the therapeutic application of eCB-based medications. In this review, we are devoted to discussing the versatile forms of eCB-mediated synaptic plasticity and dissecting currently well-studied specific cannabinoid circuits involved in behavioral domains which are closely linked to the organism’s survival and life quality, such as pain perception and stress-related emotion disorders. By gaining new insights into selective cannabinoid control in circuits, we can potentially mitigate the drawbacks of traditional pharmacology and facilitate the development of precision medicine with novel therapeutic strategies and drug discoveries.

The post Cannabinoid modulations of pain and stress related circuits appeared first on Society of Cannabis Clinicians.

]]> Medical Cannabis Alleviates Chronic Neuropathic Pain Effectively and Sustainably without Severe Adverse Effect: A Retrospective Study on 99 Cases https://www.cannabisclinicians.org/2023/09/20/medical-cannabis-alleviates-chronic-neuropathic-pain-effectively-and-sustainably-without-severe-adverse-effect-a-retrospective-study-on-99-cases/ Thu, 21 Sep 2023 00:24:25 +0000 https://www.cannabisclinicians.org/?p=29246 Medical cannabis may provide a treatment option for chronic neuropathic pain. However, empirical disease-specific data are scarce. This is a retrospective observational study including 99 patients with chronic neuropathic pain. These patients received medical cannabis by means of inhaling dried flowers with tetrahydrocannabinol content of <12–22% at a maximal daily dose of 0.15–1 g. Up to six follow-ups were carried out at intervals of 4–6 weeks. Pain severity, sleep disturbance, general improvement, side effects, and therapy tolerance at the follow-up consultations were assessed in interviews and compared with the baseline data using non-parametric Wilcoxon signed-rank test.

The post Medical Cannabis Alleviates Chronic Neuropathic Pain Effectively and Sustainably without Severe Adverse Effect: A Retrospective Study on 99 Cases appeared first on Society of Cannabis Clinicians.

]]> The Pharmacogenetics of Cannabis in the Treatment of Chronic Pain https://www.cannabisclinicians.org/2023/05/05/the-pharmacogenetics-of-cannabis-in-the-treatment-of-chronic-pain-pdf-destop-sex-differences-in-the-neuropsychiatric-effects-and-pharmacokinetics-of-cannabidiol_-a-scoping-review-pdf/ Sat, 06 May 2023 02:11:14 +0000 https://www.cannabisclinicians.org/?p=28551 The increase in the medical use of cannabis has revealed a number of beneficial effects, a variety of adverse side effects and great inter-individual variability. Association studies connecting consumption, addiction and side effects related to recreational cannabis use have led to the identification of several polymorphic genes that may play a role in the pharmacodynamics and pharmacokinetics of cannabis.

The post The Pharmacogenetics of Cannabis in the Treatment of Chronic Pain appeared first on Society of Cannabis Clinicians.

]]> Cannabis use in cancer patients: acute and sustained associations with pain, cognition, and quality of life https://www.cannabisclinicians.org/2023/05/05/cannabis-use-in-cancer-patients-acute-and-sustained-associations-with-pain-cognition-and-quality-of-life/ Sat, 06 May 2023 01:12:52 +0000 https://www.cannabisclinicians.org/?p=28524 Given the myriad of negative sequalae associated with cancer and its treatment, the palliative use of cannabis by cancer patients is increasingly of special interest. This research sought to explore associations of acute and sustained use of legal market edible cannabis products on pain, cognition, and quality of life in a group of cancer patients. In this observational study, cancer patients completed a baseline appointment, a two-week ad libitum cannabis use period, and an acute administration appointment that included assessments before cannabis use, one-hour post-use, and two-hour post-use. Participants completed self-report questionnaires related to the primary outcomes and the Stroop task as a measure of objective cognitive function.

The post Cannabis use in cancer patients: acute and sustained associations with pain, cognition, and quality of life appeared first on Society of Cannabis Clinicians.

]]> The antinociceptive activity and mechanism of action of cannabigerol https://www.cannabisclinicians.org/2023/04/22/the-antinociceptive-activity-and-mechanism-of-action-of-cannabigerol/ Sat, 22 Apr 2023 13:50:50 +0000 https://www.cannabisclinicians.org/?p=28418 Cannabis has been used for centuries to treat pain. The antinociceptive activity of tetrahydrocannabinol (THC) or cannabidiol (CBD) has been widely studied. However, the antinociceptive effects of other cannabis components, such as cannabichromene (CBC) and cannabigerol (CBG), have rarely been revealed. The antinociceptive mechanism of CBG is not yet clear, so we investigated the antinociceptive effect of CBG on different pain models, and explored the mechanism of action of CBG to exert antinociceptive effects. In the current study, we compared the antinociceptive effects of CBC, CBD, and CBG on the carrageenan-induced inflammatory pain model in mice, and the results showed that CBG had a better antinociceptive effects through intraplantar administration

The post The antinociceptive activity and mechanism of action of cannabigerol appeared first on Society of Cannabis Clinicians.

]]> Clinical Practice Guidelines for Cannabis and Cannabinoid-Based Medicines in the Management of Chronic Pain and Co-Occurring Conditions https://www.cannabisclinicians.org/2023/04/16/clinical-practice-guidelines-for-cannabis-and-cannabinoid-based-medicines-in-the-management-of-chronic-pain-and-co-occurring-conditions/ Sun, 16 Apr 2023 14:11:15 +0000 https://www.cannabisclinicians.org/?p=28353 The interest in the pharmacological applications of cannabinoids is largely increasing in a wide range of medical areas. Recently, research on its potential role in eye conditions, many of which are chronic and/or disabling and in need of new alternative treatments, has intensified. However, due to cannabinoids’ unfavorable physicochemical properties and adverse systemic effects, along with ocular biological barriers to local drug administration, drug delivery systems are needed. Hence, this review focused on the following: (i) identifying eye disease conditions potentially subject to treatment with cannabinoids and their pharmacological role, with emphasis on glaucoma, uveitis, diabetic retinopathy, keratitis and the prevention of Pseudomonas aeruginosa infections; (ii) reviewing the physicochemical properties of formulations that must be controlled and/or optimized for successful ocular administration; (iii) analyzing works evaluating cannabinoid-based formulations for ocular administration, with emphasis on results and limitations; and (iv) identifying alternative cannabinoid- based formulations that could potentially be useful for ocular administration strategies. Finally, an overview of the current advances and limitations in the field, the technological challenges to overcome and the prospective further developments, is provided.

The post Clinical Practice Guidelines for Cannabis and Cannabinoid-Based Medicines in the Management of Chronic Pain and Co-Occurring Conditions appeared first on Society of Cannabis Clinicians.

]]> When The Pharmacopoeia Fails: Cannabis for Pain https://www.cannabisclinicians.org/2023/02/24/when-the-pharmacopoeia-fails-cannabis-for-pain/ Fri, 24 Feb 2023 12:57:34 +0000 https://www.cannabisclinicians.org/?p=27830 Addressing the most compelling cannabis concern, its abuse by young people, the best meta-analysis of the data [2] reveals that even the heaviest non-medical cannabis usage in teen- agers and young adults reduces cognitive sequelae to non- statistical salience after abstinence of 72 hours with no evident permanent sequelae. No formal study has shown cognitive impairment in medical cannabis patients, and some have even documented improvement.

The post When The Pharmacopoeia Fails: Cannabis for Pain appeared first on Society of Cannabis Clinicians.

]]> The Effectiveness and Safety of Pharmaceutical-Grade Cannabidiol in the Treatment of Mastocytosis-Associated Pain: A Pilot Study https://www.cannabisclinicians.org/2023/02/18/the-effectiveness-and-safety-of-pharmaceutical-grade-cannabidiol-in-the-treatment-of-mastocytosis-associated-pain-a-pilot-study/ Sat, 18 Feb 2023 20:09:11 +0000 https://www.cannabisclinicians.org/?p=27786 Mastocytosis patients often experience a number of symptoms, including mastocytosis-associated pain that is difficult to manage due to resistance to usual antalgic treatments and/or the patient’s poor tolerance. Mastocytosis patients display significantly higher levels of indoleamine-2,3-dioxygenase-1 (IDO1) activity, leading to hyperactivation of the N-methyl-D-aspartate receptor. As cannabidiol (CBD) is known to inhibit IDO1′s enzymatic activity, we hypothesized that pharmaceutical-grade CBD is an effective treatment for mastocytosis-associated pain. Patients with non-advanced mastocytosis and refractory pain were eligible for inclusion in this observational pilot study.

The post The Effectiveness and Safety of Pharmaceutical-Grade Cannabidiol in the Treatment of Mastocytosis-Associated Pain: A Pilot Study appeared first on Society of Cannabis Clinicians.

]]> Changes in Prescribed Opioid Dosages Among Patients Receiving Medical Cannabis for Chronic Pain, New York State, 2017-2019 https://www.cannabisclinicians.org/2023/02/03/changes-in-prescribed-opioid-dosages-among-patients-receiving-medical-cannabis-for-chronic-pain-new-york-state-2017-2019/ Fri, 03 Feb 2023 20:05:51 +0000 https://www.cannabisclinicians.org/?p=27645 In spite of the huge advancements in both diagnosis and interventions, hormone refractory prostate cancer (HRPC) remains a major hurdle in prostate cancer (PCa). Metabolic reprogramming plays a key role in PCa oncogenesis and resistance. However, the dynamics between metabolism and oncogenesis are not fully understood. Here, we demonstrate that two multi-target natural products, cannabidiol (CBD) and cannabigerol (CBG), suppress HRPC development in the TRansgenic Adenocarcinoma of the Mouse Prostate (TRAMP) model by reprogramming metabolic and oncogenic signaling.

The post Changes in Prescribed Opioid Dosages Among Patients Receiving Medical Cannabis for Chronic Pain, New York State, 2017-2019 appeared first on Society of Cannabis Clinicians.

]]> Cannabis and Cannabinoid Medications for the Treatment of Chronic Orofacial Pain: A Scoping Review https://www.cannabisclinicians.org/2023/01/13/cannabis-and-cannabinoid-medications-for-the-treatment-of-chronic-orofacial-pain-a-scoping-review/ Fri, 13 Jan 2023 22:50:31 +0000 https://www.cannabisclinicians.org/?p=27459 We systematically screened for sources including a measure of effect of a cannabinoid compound on pain in COP patients that might be treated by our target specialists. Sources were selected by two authors independently. Sources were summarized by country, publication date, objective(s), COP condition(s) studied, cannabinoid(s) studied, methods, results, limitations, and conclusions. A thematic analysis and word cloud were conducted to elucidate commonalities, emphases, and gaps amongst identified sources.

The post Cannabis and Cannabinoid Medications for the Treatment of Chronic Orofacial Pain: A Scoping Review appeared first on Society of Cannabis Clinicians.

]]>